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Dr Kouchoukos.We will now proceed to the panel discussion,
which will include the presenters from the first and second ses-
sions. We have covered a number of diverse topics in both sessions
and will encourage questions from the audience. Please speak up
and challenge the people on the panel with some good questions.
I will start out with a few just to get the discussion going.
Dr Milewicz, in patients who have the familial and sporadic
type of dissections, whom do you screen with genetic testing
and with imaging?
DrMilewicz. If you have patients with familial disease, it is in-
herited in an autosomal dominant manner. There is a 50/50 risk
that they will pass on the gene to their children. So the children
need to be screened, and then the siblings need to be screened,
and then whichever parent carried the mutation, their relatives
need to be tracked down and screened.
So you can see that once you know the gene mutation, you can
exclude 50% of the relatives for follow-up. Once you have the
gene, it becomes very powerful for determining who is at risk.
The individuals with a family history probably need to be routinely
screened every 3 to 5 years, even if they have a normal aorta, until
the gene for the family is identified.
Dr Kouchoukos. Do you use genetic testing for all these
patients? This is expensive! Can you tell us how you implement
that?
DrMilewicz. The costs are falling rapidly. Right now, if you or-
der each gene individually, it is quite expensive. They just started
to set up panels of all the genes that we have identified, and that is
less than the cost of computed tomography (CT) or magnetic res-
onance imaging. So, in the big picture of things, it is a relatively
minimal cost, because once you have the gene, you can go throughres: Authors have nothing to disclose with regard to commercial support.
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The Journal of Thoracic and Cardiovascular Surgand screen other family members. Once you know the gene muta-
tion, that screening costs about $200 to $300. So you can identify
who is at risk, and cut down the amount of imaging you are doing
in the family. Knowing the gene also helps inform the management
of the affected individuals.
Dr Kouchoukos. Along those same lines for Dr Braverman,
with regard to follow-up imaging in patients who have had surgical
procedures or even those who you are following who have not had
surgery, what is your preferred method of screening? We are get-
ting pressure, as most of you know, from some of the monitoring
agencies about the cost, and also the danger in terms of radiation
with computed tomographic imaging. So how are we going to
deal with that problem?
Dr Braverman. I usually recommend magnetic resonance
screening in follow-up of individuals to avoid the radiation expo-
sure over the long term. To echo what Dianna said with regard to
the cost of doing mutation analysis in patients who have Marfan
syndrome or Loeys-Dietz syndrome clinically, and then the other
family members: once an insurance company denies coverage
for doing gene testing, it often requires a phone call to the medical
director or someone higher up in the organization to explain the
cost of continued surveillance over time. They will often change
their minds and then allow mutation analysis and pay for it. For
a lot of patients, this eliminates the worry of having the disease
and the need for repetitive screening.
I think the biggest problem is in screening the patients when you
don’t really know yet what disease they have or what mutation will
be found eventually—trying to round up all those first-degree rel-
atives and then continuing to screen them over time. We have
really gone more toward magnetic resonance screening for our
patients in the long-term follow-up.
Dr Kouchoukos. Magnetic resonance imaging is more expen-
sive than CT. Is there still a role for computed tomography?
Dr Braverman. Yes. I think there is certainly still a role for
computed tomographic scanning. It is faster and less claustrophobic.
We can do noncontrast imaging for acceptable patients whose aortas
aren’t particularly tortuous and get very accurate measurements.
Dr Kouchoukos. Are there any questions from the audience
regarding these issues?
Dr Harold G. Roberts (Fort Lauderdale, Fla). I would like to
ask a different question, specifically of Drs Mack and Svensson:ery c March 2013
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dovascular aortic repair versus the transapical approach?
Dr Mack. I think none of this is really known yet. One of the
concerns about the transapical approach is that it is more invasive
than the transfemoral, definitely. And there is a fair amount of
thought that the transaortic or direct aortic approach, even though
it still involves a thoracotomy or partial sternotomy, may be less
invasive than the transapical. So I think the experience is too small,
really, to say for sure. If the transapical approach is going to have
a significant role long term, it has to become percutaneous, and I
think there are a number of closure devices that are out there
now that are going to offer that opportunity.
But maybe, before I let Lars answer, I would ask Rudi, because
he has experience with all the approaches here.
Dr Lange. As I said in my talk, the transaortic approach was—
for us—the last resort, but now there has been a revival of trans-
aortic access, especially here in the United States. We don’t favor
the transaortic approach. I think it is more invasive and we would
rather go for the transapical. If you are used to the transapical—
once you have done a considerable number of patients—I think
it is a very safe route of access. So I don’t really see any advantage
of the transaortic route. In terms of strokes, it has not been shown
thus far that there are fewer strokes with the transaortic than with
the transapical approach. Also, as Mike pointed out, there are
transapical closure systems now, and the trials will start in Europe
soon. I think, in the future, we will have some kind of endoscopic
procedure to access the apex, and then we won’t have to do any
thoracotomy at all.
Dr Svensson. I think it also is very dependent on what your pa-
tient has. AsMike said, if you have a patient who is on 4 L or 6 L of
oxygen and you are doing an anterior thoracotomy, there is a price
to pay for that in those high-risk patients. In the patients with really
bad lung disease, I have tended to go transaortic because I think it
is a quick procedure; it is very accurate, it is very easy to do, but it
is obviously off label. In the patients who are having reoperations
and those with porcelain aortas, then I favor—obviously—a trans-
apical approach. We have had very good results with the transap-
ical approach and we think it is an excellent way of doing it, but the
transaortic patients recover very quickly and have minimal inter-
ference with breathing.
The other option is the anterior thoracotomy on the right side,
mini anterior thoracotomy, and we have used that also in patients
undergoing reoperations. They obviously are going to have a com-
puted axial tomography scan to make sure the aorta is on the right
side of the midline, and then that is a reasonable approach.
With all these approaches, including also subclavian, innomi-
nate, and carotid artery approaches, you have a lot of options;
you choose what is best for your patients. There is, I think, a differ-
ence in stroke, and so you need to discuss that with your patients.
And whether the transfemoral approach will continue to be dom-
inant I think remains to be seen with future studies.
Dr Kouchoukos. Lars, you have already commented about the
cost of the valve and the relative costs of these procedures versus
open aortic valve replacement. Could you tell us a little bit about
the relative cost of these 2 procedures at your institution?
Dr Svensson.We did a cost analysis in 2010, specifically of the
cost of the transapical versus the transfemoral procedures. This
was the actual cost, not charges to Medicare or Center forThe Journal of Thoracic and CarMedicare and Medicaid Services (CMS) or whatever insurance
company was paying for it. We were losing $4000 for every trans-
apical case and $3000 for every transfemoral procedure. So those
are the harsh economics. Now the price of the valve has gone up,
which has increased the cost, and we have decided as an institution
that we are prepared to bear the expense. We feel that we will con-
tinue to do what our conscience says is right for the patient. We,
fortunately, have the ability to carry the loss, but I know that the
University of Pennsylvania has done an analysis that shows its
loss on each valve is even higher. So it remains to be seen how
this eventually works out, especially for a commercial site.
Mike Mack, and I have spent a fair amount of time trying to
work with CMS. Initially, they were only going to reimburse us
at the price of a balloon valvuloplasty for the percutaneous
valves—and that included the price of the valves—so that was
hopeless. At least now the diagnosis-related groups (DRG) is the
same as for an open AVR.
On the professional side—negotiating with the help ofMike and
Peter Smith on the Society of Thoracic Surgeons coding commit-
tee—the way it is going to work is that, for transfemoral cases, the
payment will be 125% of an open AVR, split between the cardiol-
ogist and the surgeon. As perhaps you have seen from the draft
CMS manuscript, there has to be a surgeon and a cardiologist
involved in each case.
As a final comment, if you are going to work well with your car-
diologists, I think you need to put the money in one piggy bank,
lockbox, or whatever you want to call it, so there isn’t a battle
about the professional fees over who gets the money. That will
make a much more well-functioning team, which I think is critical
to make this a success.
DrKouchoukos.What about the cost compared with just a con-
ventional aortic valve replacement? If there is a substantial differ-
ence, is this going to have any impact as we move to patients at
lower risk who are being considered for either procedure?
Dr Svensson. I agree. That is going to be a challenge. As you
know, there is a geographic adjustment for DRG across the coun-
try. So, for example, in New York City, the DRG for an open AVR
is about $93,000; at the Cleveland Clinic, it is about $34,000. So
we have those parameters towork with, and the percutaneous valve
currently costs $32,500. How the economics play out is going to be
very interesting for the next few years, and it is going to be very
dependent on CMS. As we go into the lower risk population, we
are going to see many more young patients.
Dr Paul Achoun (Paris, France). I have 2 questions. The first
is for Dr Kari. As we have seen Dr Sch€afers present, when you
repair a bicuspid aortic valve, you have a better long-term result
when you turn it into a symmetric 180 configuration. So, Dr
Kari, when you do your reimplantation technique in a bicuspid
aortic valve, do you try to impose a 180 configuration on
your valve or do you just respect the natural ratio of the bicuspid
valve?
Dr Kari. Thank you for this interesting question. As far as I
know, Dr Sch€afers and Dr Aicher looked at valves that started
out with large angles. As far as I know, you looked at large-angle
bicuspid aortic valve (BAV) preoperatively and did not analyze the
effects of changing that angle from pre- to postoperatively. So I
think there are no data on that. We tested that in our model. We
didn’t find any positive effect of changing that angle from smalldiovascular Surgery c Volume 145, Number 3S S49
Aortic Symposium 2012 Panel 1to large. Although we looked at those angles, the purpose of the
procedure itself was not to increase the angle.
Dr Sch€afers. Can I perhaps correct a misimpression? The angle
that we analyzed was the angle with which the patients left the op-
erating room, not the preoperative angle.
Dr Kari. But do you purposely enlarge the angle?
Dr Sch€afers.Yes. Ever since we recognized the impact of com-
missural orientation, we have made an effort—whenever we re-
place the aorta (whether with sinotubular junction remodeling or
root replacement)—to increase the angle toward as much symme-
try as possible. Even if you achieve 160, that is already an
advantage in terms of durability compared with the angle of
140, or sometimes even 130, that we see on occasion.
Dr Svensson. I think the critical aspect here is the height of ap-
position of the leaflets. That’s what you really have got to work on,
apart from not narrowing it down so you end up with aortic valve
stenosis. We just analyzed 780 of our bicuspid valve repairs and
what is interesting is that, after the initial 1-year period, what
determines late outcome is a progressive increase in gradient
over time; it is virtually a linear relationship. So when you do
your repair, you need to be very careful that you end upwith a valve
that is not stenotic, because it if is stenotic, the gradient is going to
increase over time.
Dr Achouh. Thank you. My second question is for Dr Sch€afers.
When you do your remodeling technique plus annuloplasty, you
stabilize the sinotubular junction as well as the annular junction,
the annular size. In your long-term follow-up, have you ever
seen any aneurysmal dilatation of the subcommissural part of
the aorta, especially in Marfan patients?
Dr Sch€afers.No, not yet. However, I have to admit that our fol-
low-up in using this type of procedure for connective tissue disease
is shorter than that of Dr David. We are still carefully following the
patients. Up to a mean follow-up of 6 years, they are identical. We
submitted a paper to the Journal of Heart Valve Disease, and it
should come out soon, showing the results of both approaches.
Of course, for these patients it is important to have 10- and
20-year follow-up, so I think we need to discuss this question again
in 10 years.
Dr Jason Sperling (Ridgewood, NJ). I have 2 quick comments
and a question. There is a question about CT versus MRI for sur-
veillance or even initial imaging. I just wanted to point out that I
think that there are going to be continued innovations in imaging
and its impact on how we approach the care of patients with aneu-
rysms. Specifically, in our own program, we are using a technique
called retrospective gating that has increased our diagnostic yield
of type I bicuspid aortic valves dramatically. I think that is pretty
exciting.
I wanted to comment to Dr Kari regarding the late finding of
progressive aortic insufficiency after root replacement. I saw this
initially, also, after using 36-mm grafts for the roots, and I think
it is because these Dacron grafts dilate between 10% and 15%
during the early postoperative period. That may be why you are
seeing early dilatation. When we reduced the size of our root
graft—to 34 mm and sometimes to 32 mm—we did not see that
so much anymore.
My question is for Dr Milewicz. I was wondering whether you
thought that there is any danger in assigning risk simply based on
finding genetic mutations in these patients. I’m the furthest thingS50 The Journal of Thoracic and Cardiovascular Surgfrom a geneticist, but I feel that at some point we are going to
be able to identify some genetic abnormality or difference in every
patient with aneurysm, and I wonder whether it is a little premature
simply to assign risk based on finding a gene mutation.
Dr Milewicz. There are clearly genetic variants that confer
a high degree of risk, and those include the mutations in FBN1,
the TGFBR1, and 2 other mutations. So I think there is a group
of genetic variants that really do clearly define a high risk for tho-
racic aortic disease.
At the same time, within the FBN1 gene, there are genetic var-
iants that confer no risk for aortic disease. And so it does get very
complicated when you are trying to analyze genetic data. And
then, if you take a gene like MYH11, there are clearly variants
that cause thoracic aortic disease and other variants that do not.
So I do think that we have to be careful as we analyze these variants
and make sure that we are dealing with a disease-causing variant.
Geneticists know how to do that analysis, and that is why I urge
you to send your patients to a geneticist for genetic testing; it is
not as easy as ordering the test and understanding the results
immediately.
Dr Svensson. Dianna, if I could just pose one question, which
we have talked about a little in the past: There are a lot of profes-
sional athletes who are very tall—I have had 4 National Basketball
Association and a couple of National Collegiate Athletic Associa-
tion players—who don’t look as though they have Marfan syn-
drome, but have big roots and require operation. Any thoughts
about what we should do about these patients with regard to ge-
netic testing? It obviously has huge implications for these tall
men in sports.
DrMilewicz. That is a tough question. I do think that these ath-
letes do need to be tested for the known genes. I think that there are
a still a lot of marfanoid plus aneurysm genes that we haven’t iden-
tified yet. The testing is recommended in part because of the risk
for other family members and in part because it does help deter-
mine management.
Dr Kouchoukos. Let’s get back to the question about sizing of
grafts. Tirone, maybe you can comment on this. You have had sev-
eral different ways that you determine the size of grafts when you
do a valve-sparing procedure. Tell us what you do currently.
Dr David. I try to estimate the diameter of the sinotubular junc-
tion and go from there.
Dr Kouchoukos. So if the sinotubular junction measures 22
mm, what would you pick for a graft?
Dr David. A 22-mm graft, but not for reimplantation in some-
one who has a 22-mm sinotubular junction.
Dr Kouchoukos. So, essentially, now you don’t use any of your
formulas. You just estimate the size of the sinotubular junction?
Dr David. I do not. But I do worry about the size of the annulus
versus the height of the cusps. There is something I call, in the
operating room, mismatch between the sinotubular junction, the
annulus, and the size of the cusps. You don’t have to be a mathema-
tician to realize that if the annulus is larger than twice the height of
the cusps, something is badly wrong with the valve. There is a mis-
match between the size of the cusps and the size of the annulus. So
you have to reduce everything to compensate for the size of the
cusps. So I do not ignore the size of the cusps.
Patients with very small cusps are usually elderly, with sinotub-
ular junction dilation as a primary mechanism of aorticery c March 2013
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adjustment of the sinotubular junction or, at themost, a remodeling,
and they end up with small grafts—22-mm or 24-mm grafts.
Dr Kouchoukos. Now, for the reimplantation procedure, you
commented on the fact that you used cylindrical grafts more com-
monly now. You used to use larger grafts and pleat them and tuck
them and so forth. You don’t do that anymore?
Dr David. No, I don’t. It results in more bleeding in the operat-
ing room, frommore needle holes in the graft. And to be quite hon-
est, the longest follow-up we have is in cylinder grafts, and we had
the best outcomes. And, as I said only in passing, it looks as though
the younger the patient when we do the operation, the better the
long-term outcome, likely because the cusps may have an adaptive
mechanism in response to a rigid root that is greater than in a pa-
tient who is 60 years old and has cusps that are no longer elastic.
Dr Kouchoukos. I would like to show just one slide here for
a moment, if I may, that relates to what you are talking about.
This is a patient who initially was thought to have Marfan syn-
drome. We operated on her 15 years ago and did the David proce-
dure. She was subsequently found to have Loeys-Dietz syndrome,
and about a year ago, 15 years after this procedure was done, she
sustained a dissection after pregnancy and had to have a repeat pro-
cedure. This is a photograph of that implanted valve at 15 years;
the leaflets are absolutely perfect, and this is in a cylinder graft.
Can I ask the other panelists here about their techniques for sizing
grafts when they are doing the reimplantation procedure?
Dr El Khoury.What we do to size is quite simple. I know from
echocardiographic studies done by Sch€afers’ team that the sinotub-
ular junction diameter equals the height of the sinus of Valsalva,
more or less. So, after deep dissection of the aortic root, I draw
a line between the nadir of the left sinus and the sinotubular junc-
tion, and only size the height of the posterior commissure—30
mm, 32 mm, 28 mm—and I take a graft 30 mm, 32 mm, or 28
mm in diameter.
DrDavid.But the size corresponds magically to the sinotubular
junction. It is the geometry of the cylinder.
Dr El Khoury. Exactly. For me, the sinotubular junction is the
most important thing. Oneway to size the sinotubular junction is to
size this height, which is very objective.
Dr Kari. The formula introduced a couple of years ago by Dr
Feindel and Dr David—taking the aortic lumen multiplied by 2,
then multiplied by 0.67, and then adding twice the tissue thick-
ness—is used as a complement to the intuitive surgeon’s choice,
I think. It is used at Stanford.
Dr Kouchoukos. Dr David mentioned that he doesn’t use the
Valsalva graft. Do you want to tell us your feelings about the Val-
salva graft? And do any of the other panelists use a Valsalva graft
in this procedure?
Dr David. Take a look at the anatomy. The aortic root is not
spherical. The aortic root is a cylinder with 3 spheres or hemi-
spheres to make the sinuses. Gebrine El Khoury had a beautiful
slide of a cadaveric root with no sinuses. What shape was it for
Gebrine? A cylinder. Read all the work that Francis Robicsek
and Mano Thubrikar published 20 years ago on the anatomy or
the geometry of the aortic root—3 cusps within a cylinder with
3 bulges. The Valsalva graft is a sphere. You are deforming the aor-
tic annulus. I’ll bet you 10 years from now that we are going to be
sitting here and saying he was right.The Journal of Thoracic and CarDr Kouchoukos. Does anybody on the panel use the Valsalva
graft?
Dr ElKhoury. I use the Valsalva. Theway youwork on the Val-
salva tube—by scalloping and aligning the commissures to the
Valsalva—can help us to make these 3-piece sinuses. If you put
it in the way it is, as a cylinder, you will have a cylindrical root,
but if you work on aligning it—
Dr David. But he is plicating in so many places. It’s worse than
a dog’s breakfast to make a cylinder. So use a cylinder and plicate
the sinuses.
Dr El Khoury.When you are doing the second plane, it is very
easy to work with the Valsalva. When you want to place the 3 com-
missures, it is very easy, because there is a lot of discussion of how
far we should extend the straight tube or whatever. The Valsalva is
easier to work with.
Dr Kouchoukos. Let’s ask the others. Dr Sch€afers, Dr Svens-
son, Dr Mack, what is your preference?
DrMack. I use it, and I am afraid to admit it right now, but I feel
better because Rudi uses it also. Do you want to comment, Rudi?
Dr Lange. I don’t dare to get into another fight with Tirone, of
course, because we have discussed this many times. We use the
Valsalva graft exclusively and, altogether, we have about 200 pa-
tients now—maybe 50 have a straight tube and 150 have a Valsalva
graft. And to date, we don’t see any difference at all in the long-
term outcome.
Dr Svensson. I have had to reoperate on a couple of patients
with the Valsalva grafts, so I tend to lean toward what Tirone
has been saying. I have seen these patients come back with 4.5-
to 4.7-mm roots; the leaflets get pulled apart. I don’t use it and I
haven’t used it for that purpose. I think it is a great graft for bio-
logic composite valves.
As far as sizing, I looked at Tirone’s paper and wondered: Am I
really going to calculate this on every patient? And then I saw he
was using 30-mm tube grafts for most of his patients. And so that is
what I use for most patients. I use a 28-mm graft for a smallish
woman, and for a professional player or someone like that, I
may go up to 34 mm. And the other thing I do is use the formula
based on body surface area and insert a Hegar. I think that is
much more important as far as long-term durability. You want to
have at least 3 to 5 mm of apposition to maintain good function
of those leaflets.
Dr Sch€afers. I don’t use the Valsalva graft. My feeling—and
this is intuitive—is that the operation must include optimal height
of the commissures. You have to place them as high as possible. I
have done a number of reoperations from other centers where com-
missural height was the primary problem. The Valsalva graft
limits, by definition, the highest point at which I can place the com-
missures. This is why I prefer the tube graft, because it is unlim-
ited. I can simply place the commissures as high as I want.
Dr Kouchoukos. Good point.
Dr Francois Bouchart (Rouen, France). I want to ask a ques-
tion about aortic root dilation. If you have a youngwoman, 16 to 18
years old, with Loeys-Dietz syndrome and an aortic root of 40 mm
or 42 mm, you plan to change it. Where do you stop on the aorta?
We have good results with surgery of the aortic arch, especially in
a nonacute setting, and why not replace the aortic arch? Would it
seem unreasonable?
Dr Kouchoukos. Duke Cameron, do you want to respond?diovascular Surgery c Volume 145, Number 3S S51
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on that. I did mention in my talk that in the younger Loeys-Dietz
patients in whomwe didn’t replace even the entire ascending aorta,
there was a small remnant of distal aorta proximal to the innomi-
nate with some dilatation that we really haven’t seen frequently in
Marfan patients. So I think a more aggressive replacement of the
aorta makes some sense, but I think you have got to be able to
do an arch replacement with a very low operative risk to justify
an approach like that.
Dr Ziad Hanhan (Jersey City, NJ). I have a clinical question,
a hypothetical situation. A 30-year-old woman with a type A dis-
section that is limited to the ascending aorta has a bicuspid aortic
valve, and the aortic root is 4.5 cm. Which operation would you
perform? Would you go for the Bentall prophylactically or just re-
place the ascending aorta, if you could?
Dr Sch€afers. In a small woman, a 4.5-cm root means that it is
markedly enlarged. There are no published prognostic data show-
ing the degree or the likelihood of root dilatation in that patient. On
the other hand, if we index it for patient size and then apply com-
mon sense, I think one can make a strong argument in favor of root
replacement, whether it is a Bentall replacement or maybe a valve-
preserving replacement.
Dr Hanhan. Just to follow up, is that a consensus for the com-
munity cardiothoracic surgeon who can do a Bentall but also could
lower the risk by just replacing the ascending aorta in an acutely
dissected situation? I’m just trying to get some controversy here.
Dr David. Save the patient’s life. Do the simplest possible op-
eration so she goes home alive, and then send her to somebody else
to do a valve-sparing operation later on.
Dr Luca Botta (Milan, Italy). I have a question for Drs El
Khoury and Sch€afers. I would like to know from them if there is
still a role for selective replacement of the noncoronary sinus in
a bicuspid valve in a patient with dilatation of the ascending aorta
and a bicuspid valve.
Dr Sch€afers. While Gebrine is thinking about the answer, I
think—but this is completely personal—no. Why don’t I do it?
We don’t have good information on the ascending aorta, but we
know from the aortic isthmus that whenever we introduce pros-
thetic material in an asymmetric fashion—and I am thinking of
the patch plasty that was done 30, 40 years ago for coarctation re-
pair—this resulted in a relatively high incidence of aneurysm for-
mation. For that reason, even though at times it looks like the
noncoronary sinus is the main problem, I prefer to do a symmetric
operation—that is, replace all sinuses.
Having said that, it is often proposed that 1 sinus is larger than
the others and the operation should maybe include only that 1 si-
nus. At this time, I am not aware of any long-term data showing
that there is a disadvantage in doing it.
Dr El Khoury. I agree totally, but I think one of the first things
to think about is the age of the patient. If the patient is quite old—
50, 60 years—I think replacing the noncoronary sinus can be
a good idea, because the aortoventricular junction is stable and
there is no risk for further dilation at the level of the aortoventric-
ular junction. If the patient is young—20, 25, or 30 years—I think
we should be more aggressive and do a symmetric reconstruction
of the aortic root.
Dr Kouchoukos. I would like to ask Dr Lange: You showed
some data indicating that the percutaneous valves now areS52 The Journal of Thoracic and Cardiovascular Surgapproximately 30% or so of all the valve replacements in Ger-
many. Has that reduced the number of open aortic valve replace-
ments or are these in addition to the standard aortic valve
replacements?
Dr Lange. The statistics show very clearly that percutaneous
valve surgery has reduced the number of open procedures. This
trend started about 2 years ago. There was a plateau for 2 years,
and now the number of open procedures is decreasing.
Dr Kouchoukos. By what percent would you estimate?
Dr Lange. I would say by perhaps 10%.
DrAchouh. I would like to ask DrMilewicz: In the setting of an
aortic surgery program, do you recommend genetic counseling
whenever a patient comes in with an acute dissection or do we
have to have some family history of dissection or something else?
Dr Milewicz. I think if the patient is young or there is a family
history, genetic counseling is warranted. The treatment guidelines
state that you should work up the family members, but that can be
done by the cardiologist.
Dr Achouh. If we don’t have any apparent family history, ac-
cording to the patient, do you still send him for genetic counseling?
DrMilewicz. I would if the patient was young,<50 or 55 years.
Dr Hitoshi Ogino (Suita, Japan).My question is to Drs David,
El Khoury, and Sch€afers. My concern is about cusp repair tech-
nique. There are actually 2 techniques: central plication and an-
other technique of reinforcement, which Dr David mentioned, as
well as resuspension, to which Dr El Khoury alluded. For what
cusp pathology are both techniques suitable?
Dr David. The video I showed you was representative of a nor-
mal cusp. If the cusp is normal in thickness, I think plication is the
way to go. However, if the free margin you can see is over-
stretched, is paper thin, or even thinner than paper, then I reinforce
with a double layer of Gore-Tex, one very close to the free margin,
and a second layer of Gore-Tex a few millimeters below.
Two years ago when I gave a talk on this here, I showed a video
of how we do it, and I showed the result of a patient who had had
Gore-Tex 13 years earlier and came back for reoperation because
of mitral valve repair, in whom we explored the aortic valve. You
could not see the Gore-Tex anymore. It is identical to Gore-Tex in
the mitral chordae tendinae. It becomes totally covered by fibrous
tissue and reinforces the free margin. I think Gebrine, whom I
trained 15 years ago, took this to a new level. To be quite honest,
I was very conservative initially. By watching him do it more
freely, I expanded the indications as well. And they have pub-
lished this; in >100 cases now, reinforcement with Gore-Tex
seems to stabilize the cusps. By doing this, you expand the indica-
tion of aortic valve sparing, particularly in younger patients—peo-
ple <30 or 40 years of age, in whom you don’t want to put
a mechanical valve and keep them on anticoagulation for
a lifetime.
Dr Kouchoukos.Duke, let me ask you a question that relates to
this. What is your current indication to use a mechanical valve in
a patient with either Marfan or Loeys-Dietz syndrome? When do
you decide to use a mechanical prosthesis and a composite graft?
Dr Cameron. Essentially, only if the patient has requested it up
front. We still have some patients who have other family members
who have composite grafts who have done well with them, and
they actually ask for a mechanical valve. The other patients would
be those who already have a mechanical mitral valve. But most ofery c March 2013
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for a biologic Bentall as their backup.
Dr Kouchoukos. Have you had to do repairs on any of the leaf-
lets in this group of patients?
DrCameron. In theMarfan group, it is about 10% to 15%, and
in our group of patients, the commissures are so thin that we have
really not been able to do free-edge suturing, so we will do a mid-
leaflet plication. I think only 1 of those Loeys-Dietz patients had
a midleaflet plication.
Dr Manu N. Mathur (Sydney, Australia).With the valve-spar-
ing roots, most of the patients have mild or minimal aortic insuffi-
ciency (AI), because in the patients with root aneurysms with
severe AI, you look at the leaflets and you think that this is not go-
ing to give a good long-term result. I would like to know from all
the surgeons on the panel what proportion of their cases when they
are doing a valve-sparing root actually have severe AI.
Dr David. You saw in our slide that approximately half of
our patients had moderate AI and one fourth had severe AI at
the time of the operation. I don’t think severe AI necessarily
means bad cusps in patients who have aortic root aneurysm. It
means the root is characterized by what I said before: there is
a mismatch between the surface area of the cusps and the orifice
of the cusps. Some cusps tolerate it very well; other ones fall
apart.
I don’t want to convey the message that I repair every aortic
valve, by a long shot. We still do 4:1 Bentalls in Toronto versus
valve sparing. So it is not that common. These are highly selected
patients. But if the cusps are prolapsing, we fix them if the sub-
stance is reasonable.
Dr Mathur. If the roots are>6 cm, are you still doing valve
sparing?
Dr David. Even 70 mm or 80 mm. It doesn’t matter. It all de-
pends on the cusps. Remember, sinus of Valsalva dilatation does
not cause aortic insufficiency. What causes aortic insufficiency is
annular and sinotubular junction dilatation. You can rupture the si-
nus of Valsalva into the right ventricle. Like children, they have
a competent aortic valve and there is a hole in the sinus, and the
valve stays competent. So you can have a sinus of Valsalva as
big as you like. The 2 things that play on the function of aortic
insufficiency are the sinotubular junction and the diameter of the
aortic annulus.
Dr Mathur. You said in Toronto it’s 4:1, root replacement ver-
sus valve sparing.
Dr David. We do about 120 Bentalls a year.
Dr Mathur.Why aren’t they having valve-sparing roots? Why
aren’t they suitable?
Dr David. They are bicuspid, calcified; they are bad aortic
valves. We can’t repair some of the Marfan valves; the cusps are
all destroyed. In those, of course, you replace them. The whole
key is the quality of the cusps. If the cusps are of reasonable qual-
ity, I think it is a good and lasting operation.
Dr Sch€afers. In our experience, roughly 70% of the patients
have either grade 3 or grade 4 aortic regurgitation,maybe even a lit-
tle more. I don’t have the exact figures. I think it is a good question,
and so far as a rule of thumb, if there is minimal regurgitation,
there is also minimal alteration of cusp geometry. If there is rele-
vant aortic regurgitation, there is a very high likelihood that you
end up with prolapse of at least 1 if not more cusps. So when thereThe Journal of Thoracic and Caris severe aortic regurgitation, and you go for a valve-preserving
operation, you must expect cusp prolapse. You must familiarize
yourself with the techniques of assessing cusp geometry and of
correcting the prolapse.
Dr Svensson. I would add to what Tirone is saying that as far as
size and regurgitation amount by themselves, those are not reasons
not to do a David reimplantation. In our population, we looked at
this a while ago: 5% of our patients had 4þAI. So that is not a rea-
son to exclude a patient.
The big question is whether there are fenestrations in the leaf-
lets, and how big they are. So, as Tirone was saying, leaflet quality
is paramount. If you have good leaflet quality, then you can always
repair the valve if need be, and then do a David reimplantation; you
don’t have to replace the valve. So, as other people have said, it
takes judgment over time to decide in which patients you can
keep the leaflets.
The other thing I would say as a rule of thumb is that in those
patients with more than 2 leaflets that are prolapsing, you probably
shouldn’t try to do a David. It usually doesn’t work out. It is very
easy to correct the prolapse if there is one leaflet prolapsing.With 2
leaflets, you can hitch up 1 commissure and reimplant at the higher
level, but when you have 3 leaflets prolapsing, then it usually is not
going to work.
Dr Said A. B. Soliman (Cairo, Egypt). My question is for Drs
El Khoury and Sch€afers about patients with bicuspid aortic valve.
Sometimes we are faced with patients who have mild stenosis, not
insufficiency alone, with a gradient of 40 mm or maybe 50 mm. In
such cases, do you proceed with valve sparing when there is a mild
stenosis and some calcification of the leaflets? A second question
also is about using annular stabilization. Is there is a difference be-
tween the Gore-Tex stitch and the annular ring?
Dr El Khoury. I think for the gradient, the whole issue is the
quality of tissue. You can have a normal bicuspid aortic valve
with a huge dilation of the aortic root and a big gradient. Now, if
you do sparing surgery, the gradient will disappear because you
have more motion of the leaflet.
The question is different if the leaflets are calcified. I was quite
aggressive some years ago; now I have become a little bit less so. If
the bicuspid valve is calcified, I will replace the valve unless it is
really localized calcification on the raphe or at the base of the leaf-
let. So a gradient, per se, is not really a contraindication to valve
sparing, providing that you have good quality of tissue. If there
is no calcification, we go ahead.
Regarding annuloplasty, for both bicuspid and tricuspid valves,
my preferred technique for stabilization is reimplantation. I have
never tried the Gore-Tex stabilization. The only comment I can
make is that when we are repairing the bicuspid valve, we like
to have what I will call selective annuloplasty of the anterior
part of the bicuspid annulus. I am not sure, and I will ask Joachim
for his comment, but with a circular annuloplasty, there is no selec-
tive effect. We are reducing the whole circumference. I don’t know
whether I am right.
Dr Sch€afers. Let me answer the second question first. At this
point I have not seen a disadvantage in terms of root geometry
of the circular annuloplasty via a suture. Early on, we had a couple
of complications. This was when we used Ethibond, and we had 2
or 3 patients with secondary erosion of the membranous ventricu-
lar septum. This is something that, of course, you will not expect ordiovascular Surgery c Volume 145, Number 3S S53
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to have been largely eliminated just by changing the material.
On the other hand, I said these are early results that I presented
today, and probably we are not dealing with the ideal implant yet.
My vision is to have an implant that you can pass through muscle
that has a bigger diameter than a suture and therefore better stress
distribution.
To come back to your question regarding the gradient, I had
a similar experience in the past. I thought it was very easy to cut
out the calcium, suture in a patch, or just peel off calcium if there
was a calcific bar. I have become less enthusiastic about this. Inser-
tion of a patch into, for instance, the area of the median raphe is an
independent predictor of failure, and I have become very conserva-
tive regarding insertion of patch material in a bicuspid valve. It is
different for a tricuspid valve. The only 2 patients on whom I had to
operate for aortic stenosis 10 years and 11 years after remodeling
a bicuspid valve were patients in whom I peeled a limited calcific
bar off the noncoronary cusp at the initial operation. Still, the op-
eration had a durability of 10 or 11 years. At reoperation, the valve
was completely calcified. So, probably, a bicuspid valve that al-
ready exhibits calcifications at the time you touch it is not
a good substrate for valve preservation.
Dr Soliman. So you proceed, from the start, to change these
valves?
Dr Sch€afers. Yes. Today, if I were to operate and see calcifica-
tions, if it were a very young patient and I could get by with just
resecting the calcium and making the aorta smaller, and I still
would have enough tissue left, I would go for a direct readaptation.
If there were more extensive calcification, I would strongly recom-
mend replacement.
Dr Jean E. Bachet (Abu Dhabi, United Arab Emirates). The
previous question prompts me to ask Gebrine and Hans Sch€afers
the following questions. When we see your results and your video,
it seems very simple to repair those valves, but I am convinced that
it is not so simple; otherwise, it would be much more popular. And
you are speaking about decalcifying, etc. What exactly is the pro-
portion of the patients with an aortic valve problem that you repair
and that you replace in your department?
And you said, for instance, that the quality of the valve, in your
own words, is the only criterion. How do you appreciate that? Is it
just that you look at the valve and say, ‘‘This is a good one; this is
a bad one?’’ In other words, what are your objective criteria to
decide whether you will replace a valve or repair it?
Dr Sch€afers. The proportion of repair in our total volume is
37% to 38%. It was up to 40% a few years ago, and then we be-
came a little more conservative in some of the bicuspid valves.
Objective criteria? One is calcification, which we have already
commented on. Dr Svensson also mentioned the presence of mul-
tiple fenestrations. My feeling is that 1 or 2 fenestrations can be
closed, although it is a more complex procedure. But if there are
3, 4, or 5 fenestrations, I think that valve is better replaced.
In addition, there is the important and interesting question of
cusp retraction in rheumatic valve disease, which I think creates
a suboptimal substrate for repair. Currently I am fighting through
the editorial comments concerning a publication that I submitted
to the Journal of Thoracic and Cardiovascular Surgery that looks
at cusp height—at what I call geometric height, just the amount of
tissue. A normal tricuspid valve has a cusp height of 20 mm. If it isS54 The Journal of Thoracic and Cardiovascular Surg17 mm in an adult patient, this cusp is already retracted, and for the
bicuspid valve it is similar. For the 1 large cusp, the mean is 23
mm, and if it is 20 mm, it is borderline; if<20 mm, that amount
of tissue is so little that I would recommend not repairing the valve,
considering the cusp to be retracted. With these valves we would
then go for replacement.
Dr El Khoury. I agree totally. The only thing that I can say is
that if you have an aneurysmal problem, and you have the echocar-
diographic and surgical assessment that the valve is normal, it can
be preserved in 100% of patients.
In a patient with aortic regurgitation, the problem is a little bit
different. It depends on the quality of tissue, for sure, but what is
really more important is the quality of tissue at the end of surgery.
Let’s say there is a small calcification, a small thickening, or some-
thing like that, and you can resect it and restore good motion of the
leaflet, and at the end of the surgery we have good results—
Dr Sch€afers. Give us a number. By the way, for us, the rate of
repair is 40% of total volume; 85% for aortic regurgitation. Gebr-
ine, you say the same numbers. Total volume repair and repair in
regurgitation—give us the percentage.
Dr El Khoury. Eighty to 90%.
Dr Bachet.Does age enter into your decision? In other words, if
you have a patient who is 70 years old, would you spend time re-
pairing his valve instead of putting in a nice pericardial valve,
which will take 45 minutes and which will last 20 years?
Dr El Khoury. It depends. If it is a dilated root, you will do
a Bentall. There is a big difference in time between Bentall and
valve-sparing surgery.
Dr Bachet. I am not speaking of dilatation of the root. Don’t
change the subject.
Dr El Khoury. If you have only prolapse of the noncoronary, of
the right, I think you can finish the operation also with 2 stitches. If
you are confident in your technique, you can do a repair; you can
do whatever you decide. The major thing is to be confident in your
surgery.
Dr Carlo Antona (Milan, Italy). Reinforcement of the free
margin with Gore-Tex is an excellent technique, but I think that,
today, we can use it only for anatomic stabilization, but not for
the physiology of the valve. We have demonstrated that when
you obtain good coaptation, the free margin is completely des-
tressed, and this is the reason you can plicate—only plicate—for
a short prolapse without reinforcing the free margin. I have had ex-
cellent results. We can reinforce the free margin to resolve a small
degree of prolapse, but not to stabilize the valve. It is only an an-
atomic stabilization, because with finite elements we show that the
valve is completely destressed. It means that, in my view, the most
important problem is to have nice coaptation, more than 4 mm, 5
mm, 6 mm of coaptation.
Dr David. I agree entirely. You restore anatomy first, and then
if there are 2 or 3 large fenestrations you are concerned are going
to rupture, it doesn’t matter how good a coaptation you have. My
slide shows well a very large fenestration that extends to the cen-
tral portion. That kind of cusp should be repaired or the valve re-
placed. So, yes, one should use plication of the central portion to
repair prolapse, but in addition to that, if the cusps are of bad
quality, reinforce with Gore-Tex—7-0 Gore-Tex, 2 or 3 layers
sometimes. You are going to guarantee longer durability for
the repair.ery c March 2013
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free suspension. Now, I think, something has changed—only ana-
tomic stabilization.
Dr David. No, I never use Gore-Tex to correct prolapse. From
day 1, from my very first publication, I said I used Gore-Tex to re-
pair large fenestrations. Prolapse you repair by plication. You canThe Journal of Thoracic and Carcorrect 1 mm or 2 mm of prolapse by suspending a bit, but if the
prolapse is 0.5 cm, you should not rely on the Gore-Tex to fix
the prolapse.
Dr Kouchoukos. Our time is up. I want to thank all of the pan-
elists for their presentations and comments, and the audience for
their attention.diovascular Surgery c Volume 145, Number 3S S55
